Tags

Type your tag names separated by a space and hit enter

Haloperidol vs. ondansetron for the prevention of postoperative nausea and vomiting following gynaecological surgery.
Eur J Anaesthesiol. 2007 Feb; 24(2):171-8.EJ

Abstract

BACKGROUND AND OBJECTIVE

Ondansetron is widely used for the prophylaxis of postoperative nausea and vomiting, while haloperidol is an antiemetic that lacks recent data on efficacy and adverse effects.

METHODS

In this prospective, randomized, double-blinded study involving 93 females undergoing gynaecological procedures under general anaesthesia, we compared the efficacy and adverse effects of prophylactic haloperidol 1 mg intravenous and ondansetron 4 mg intravenous vs. placebo.

RESULTS

During the overall observation period (0-24 h), in the haloperidol, ondansetron and placebo groups respectively, the incidence of nausea and/or vomiting was 40.7% (11/27), 48.2% (13/27) and 55.5% (15/27), and the need of rescue antiemetics was 22.2% (6/27), 44.4% (12/27) and 40.7% (11/27), with P values >0.05 among the three groups. During the early observation period (0-2 h), in the haloperidol, ondansetron and placebo groups respectively, the incidence of nausea and/or vomiting was 13.7% (4/29), 26.6% (8/30) and 43% (13/30), and the need for rescue antiemetics was 6.8% (2/29), 26.6% (8/30) and 36.6% (11/30). Between haloperidol and placebo groups, the P value was 0.04 for nausea and/or vomiting, and was 0.01 for rescue antiemetics, in addition to lower nausea scores (P = 0.03). During the late observation period (2-24 h), no significant difference was shown among the three groups.

CONCLUSION

The prophylactic administration of 1 mg intravenous haloperidol or 4 mg ondansetron, in female patients undergoing gynaecological surgery, did not improve the overall incidence of nausea and/or vomiting vs. placebo. However, haloperidol 1 mg proved to be an effective antiemetic in the early observation period without significant adverse effects.

Authors+Show Affiliations

American University of Beirut, Department of Anesthesiology, Medical Center, Beirut, Lebanon. mm01@aub.edu.lbNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16938159

Citation

Aouad, M T., et al. "Haloperidol Vs. Ondansetron for the Prevention of Postoperative Nausea and Vomiting Following Gynaecological Surgery." European Journal of Anaesthesiology, vol. 24, no. 2, 2007, pp. 171-8.
Aouad MT, Siddik-Sayyid SM, Taha SK, et al. Haloperidol vs. ondansetron for the prevention of postoperative nausea and vomiting following gynaecological surgery. Eur J Anaesthesiol. 2007;24(2):171-8.
Aouad, M. T., Siddik-Sayyid, S. M., Taha, S. K., Azar, M. S., Nasr, V. G., Hakki, M. A., Zoorob, D. G., & Baraka, A. S. (2007). Haloperidol vs. ondansetron for the prevention of postoperative nausea and vomiting following gynaecological surgery. European Journal of Anaesthesiology, 24(2), 171-8.
Aouad MT, et al. Haloperidol Vs. Ondansetron for the Prevention of Postoperative Nausea and Vomiting Following Gynaecological Surgery. Eur J Anaesthesiol. 2007;24(2):171-8. PubMed PMID: 16938159.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Haloperidol vs. ondansetron for the prevention of postoperative nausea and vomiting following gynaecological surgery. AU - Aouad,M T, AU - Siddik-Sayyid,S M, AU - Taha,S K, AU - Azar,M S, AU - Nasr,V G, AU - Hakki,M A, AU - Zoorob,D G, AU - Baraka,A S, Y1 - 2006/08/29/ PY - 2006/07/31/accepted PY - 2006/8/30/pubmed PY - 2007/4/5/medline PY - 2006/8/30/entrez SP - 171 EP - 8 JF - European journal of anaesthesiology JO - Eur J Anaesthesiol VL - 24 IS - 2 N2 - BACKGROUND AND OBJECTIVE: Ondansetron is widely used for the prophylaxis of postoperative nausea and vomiting, while haloperidol is an antiemetic that lacks recent data on efficacy and adverse effects. METHODS: In this prospective, randomized, double-blinded study involving 93 females undergoing gynaecological procedures under general anaesthesia, we compared the efficacy and adverse effects of prophylactic haloperidol 1 mg intravenous and ondansetron 4 mg intravenous vs. placebo. RESULTS: During the overall observation period (0-24 h), in the haloperidol, ondansetron and placebo groups respectively, the incidence of nausea and/or vomiting was 40.7% (11/27), 48.2% (13/27) and 55.5% (15/27), and the need of rescue antiemetics was 22.2% (6/27), 44.4% (12/27) and 40.7% (11/27), with P values >0.05 among the three groups. During the early observation period (0-2 h), in the haloperidol, ondansetron and placebo groups respectively, the incidence of nausea and/or vomiting was 13.7% (4/29), 26.6% (8/30) and 43% (13/30), and the need for rescue antiemetics was 6.8% (2/29), 26.6% (8/30) and 36.6% (11/30). Between haloperidol and placebo groups, the P value was 0.04 for nausea and/or vomiting, and was 0.01 for rescue antiemetics, in addition to lower nausea scores (P = 0.03). During the late observation period (2-24 h), no significant difference was shown among the three groups. CONCLUSION: The prophylactic administration of 1 mg intravenous haloperidol or 4 mg ondansetron, in female patients undergoing gynaecological surgery, did not improve the overall incidence of nausea and/or vomiting vs. placebo. However, haloperidol 1 mg proved to be an effective antiemetic in the early observation period without significant adverse effects. SN - 0265-0215 UR - https://www.unboundmedicine.com/medline/citation/16938159/Haloperidol_vs__ondansetron_for_the_prevention_of_postoperative_nausea_and_vomiting_following_gynaecological_surgery_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=16938159.ui DB - PRIME DP - Unbound Medicine ER -